Darzalex combo up for EU approval for multiple myeloma patients
Johnson & Johnson (J&J) is asking regulatory authorities in the European Union to approve a combination treatment based on the subcutaneous, or under-the-skin, formulation of Darzalex (daratumumab) for adults with newly diagnosed multiple myeloma. Known as D-VRd, the quadruple therapy includes subcutaneous Darzalex — sold as Darzalex…